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Muscarinic Supersensitivity and Impaired
Receptor Desensitization in G Protein±Coupled
Receptor Kinase 5±Deficient Mice
One important mechanism for receptor desensitiza-
tion is the uncoupling of the activated receptors from
further stimulation of their G proteins. This form of de-
sensitization is mediated by the phosphorylation of the
activated receptor by members of the family of G pro-
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ceptor from activating more G proteins despite theDuke University Medical Center
Durham, North Carolina 27710 continued binding of agonist (Pitcher et al., 1998). Six
distinct GRK genes are known, named GRK1 through
GRK6, which can be classified into three distinct groups
based on gene structure, sequence similarity, function,Summary
and regulation (Premont et al., 1995). Several GRK en-
zymes are found widely throughout the body and in theG protein±coupled receptor kinase 5 (GRK5) is a mem-
brain, but the relative importance of each GRK in anyber of a family of enzymes that phosphorylate acti-
tissue is presently unclear (Pitcher et al., 1998).vated G protein±coupled receptors (GPCR). To ad-
GRK5 is the best-characterized member of the GRK4dress the physiological importance of GRK5-mediated
subfamily of GRKs, which also contains GRK4 and GRK6regulation of GPCRs, mice bearing targeted deletion
(Premont et al., 1995). The GRK5 mRNA is expressedof the GRK5 gene (GRK5-KO) were generated. GRK5-
widely in brain and peripheral tissues, with the highestKO mice exhibited mild spontaneous hypothermia as
expression evident in heart, lung, and placenta; how-well as pronounced behavioral supersensitivity upon
ever, the expression pattern of the GRK5 protein ischallenge with the nonselective muscarinic agonist
not well characterized. In model systems, GRK5 hasoxotremorine. Classical cholinergic responses such
been shown to be able to phosphorylate several dis-as hypothermia, hypoactivity, tremor, and salivation
tinct GPCR types, including rhodopsin, b2-adrenergic,were enhanced in GRK5-KO animals. The antinocicep-
M2-muscarinic, secretin, endothelin ET1, angiotensintive effect of oxotremorine was also potentiated and pro-
AT1, and thyroid-stimulating hormone receptors (Ingleselonged. Muscarinic receptors in brains from GRK5-KO
et al., 1993; Kunapuli et al., 1994; Premont et al., 1994;mice resisted oxotremorine-induced desensitization,
Menard et al., 1996; Pitcher et al., 1998; Tsuga et al.,as assessed by oxotremorine-stimulated [35S]GTPgS
1998). Overexpression of GRK5 in the heart revealedbinding. These data demonstrate that elimination of
that the exogenous GRK5 can augment desensitizationGRK5 results in cholinergic supersensitivity and im-
of the b-adrenergic±mediated but not the angioten-paired muscarinic receptor desensitization and sug-
sin II±mediated contractile responses (Rockman et al.,gest that a deficit of GPCR desensitization may be an
1996). However, physiological substrate receptors forunderlying cause of behavioral supersensitivity.
endogenous GRK5, and the importance of GRK5 for
maintaining normal physiological responses, remain un-
Introduction known.
To examine the function of GRK5, the mouse GRK5
Many important neuromodulators function through acti- gene was inactivated by homologous recombination.
vation of specific pre- and postsynaptic G protein± Mice lacking functional GRK5 were then assessed for
coupled receptors (GPCRs). These include the adrener- their ability to adapt when challenged with GPCR ago-
gic, muscarinic, serotonergic, and dopaminergic systems, nists. Strikingly, these animals are supersensitive to
as well as a great variety of peptidergic systems. Binding challenge with the muscarinic agonist oxotremorine,
of such substances to their specific cell surface recep- and display an apparent lack of desensitization of mus-
tors leads to activation of the intracellular G protein± carinic receptor responsiveness.
mediated effector pathways, such as adenylyl cyclase,
phospholipase C-b, or various ion channels, which then
Resultsalter neuronal responsiveness (Dickey and Birnbaumer,
1993). One notable feature of these G protein pathways
Generation of GRK5-KO Miceis that the cell surface receptors are subject to precise
To begin to address the functions of GRK5 in vivo, theregulation of their sensitivity. Prolonged or repeated ex-
GRK5 gene was targeted by homologous recombinationposure of a receptor to its agonist leads to diminished
in embryonic stem (ES) cells, as shown in Figure 1A.responsiveness of the receptor to further stimulation, or
The targeting construct introduced two loxP sites intodesensitization (Hausdorff et al., 1990).
the gene, flanking exons 7 and 8, as well as a selectable
marker gene cassette also flanked by loxP sites. Tran-
sient transfection of a targeted ES cell clone with cre§ To whom correspondence should be addressed (e-mail: lefko001@
recombinase led to loss of the sequences between thereceptor-biol.duke.edu).
‖ These authors contributed equally to this work. loxP sites, leaving a deleted GRK5 gene (GRK5-KO) with
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Figure 1. Targeted Inactivation of the Mouse
GRK5 Gene
(A) Schematic diagram of the wild-type GRK5
locus, the GRK5/lox targeting vector, the inte-
grated targeting construct, and the Cre re-
combinase-deleted GRK5 locus (GRK5-KO).
GRK5 exons are shown as open boxes and
numbered from the first coding exon ac-
cording to Premont et al. (1999). LoxP sites
are shown as filled triangles, and the location
of the Southern blot probe as a filled box.
Relevant SpeI restriction sites are indicated.
(B) Genotyping of targeted GRK5-KO mice.
The wild-type and GRK5-KO loci were distin-
guished by triplex PCR amplification. The
wild-type GRK5 locus gives a 410 bp band,
while the GRK5-KO locus gives a 315 bp
band, as indicated by the arrows.
(C) GRK5 protein expression by Western
blotting. Brain proteins from wild-type and
GRK5-KO animals were subjected to immu-
noblotting using an anti-GRK5 antiserum (Op-
permann et al., 1996). GRK5-KO homozygote
animals exhibit a loss of the 67 kDa immuno-
reactive band compared with wild-type ani-
mals (arrow). Similar blots were also obtained
with brainstem, hypothalamus, and striatum
(data not shown). The 68 kDa band may repre-
sent the closely related GRK6 or GRK4 pro-
tein, which cross-reacts with this antiserum.
no exons 7 and 8, and no inserted marker genes. Exons Behavioral Responses to Muscarinic Agonist
7 and 8 encode critical subelements I through III of the The central cholinergic system is known to be involved
protein kinase catalytic domain (Hanks et al., 1988). The in thermoregulation (Lomax, 1970). Muscarinic agonist
GRK5-KO gene contains intact exons 1±6, and could treatment produces rapid and profound hypothermia,
potentially produce a transcript encoding amino acids and this response has been used classically to assess
1±178, but exon 9 would be spliced out of frame and lead muscarinic receptor sensitivity in vivo (Dilsaver and
to termination after the addition of 16 novel residues. Alessi, 1988). In light of the subtle differences in core
Proper targeting of the GRK5 gene, and subsequent temperatures, we challenged mice with the nonselective
animal genotyping, was assessed using triplex polymer- muscarinic agonist oxotremorine (Gomeza et al., 1999)
ase chain reaction (PCR) amplification (Figure 1B). West- to assess potential changes in hypothermic parameters
ern blot analysis of GRK5 protein expression in brain in the GRK5-KO mice. In this paradigm, the GRK5-KO
membranes reveals the presence of GRK5 immunoreac- mice exhibited a more pronounced and longer lasting
tivity in wild-type mice but not in the GRK5-KO animals depression in body temperature than did wild-type con-
(Figure 1C). The upper band may represent the GRK4 trol mice (Figure 2A). In contrast, central hypothermic
or GRK6 subtypes that are also recognized by this responses to the serotonin 5-HT1A receptor agonist
monoclonal antibody. 8-OH-DPAT (Overstreet et al., 1998) did not differ be-
tween genotypes (Figure 2B).
Initial Characterization of GRK5-KO Mice It is well established that activation of central musca-
The homozygote GRK5-KO mice are viable and present
rinic pathways results in a characteristic set of manifes-
no gross anatomical differences nor striking behavioral
tations, known as cholinergic syndrome. These behav-abnormalities. In locomotor activity tests, knockout
iors include hypoactivity, tremor, and salivation, as wellmice were not different from wild-type littermates in
as hypothermia. All of these behaviors are consideredhorizontal and vertical activities nor stereotype scores
to be dependable measures of the responsiveness of(data not shown). Classical locomotor responses (Wil-
central muscarinic receptors (Dilsaver and Alessi, 1988;cox et al., 1980; Wang et al., 1997) to the D1/D2 dopa-
Gomeza et al., 1999). Oxotremorine treatment producedmine receptor agonist apomorphine (see Figure 3B) and
more potent and longer lasting depression of horizontalcocaine (data not shown) also did not differ between
activity in mutant versus wild-type mice (Figure 3A). No-GRK5-KO and littermate controls. The only intrinsic dif-
tably, the dopamine receptor agonist, apomorphine,ference detected between untreated GRK5-KO and
produced similar climbing responses in both genotypeswild-type animals was in core body temperature, which
(Figure 3B). Further, mice challenged with oxotremorinewas z0.98C lower in GRK5-KO mice (basal core temper-
exhibited increased and prolonged tremor (Figure 4A)ature was 37.3 6 0.098C , n 5 30, in wild-type animals
and 36.4 6 0.18C, n 5 28, in GRK5-KO mice). and salivation (Figure 4B). Thus, GRK5-KO mice exhibit
Muscarinic Supersensitivity in GRK 5±Deficient Mice
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Figure 2. Hypothermic Responses to Musca-
rinic and Serotonergic Agonists in Mutant and
Wild-Type Mice
(A) Effect of oxotremorine (0.05 mg/kg, i.p.)
on body temperature. (Inset) Averaged drop
in body temperature (maximal hypothermia)
measured 30 min after drug administration.
(B) Effect of 5HT1A receptor agonist ((1)-8-
OHDPAT, 0.2 mg/kg, subcutaneously) on
body temperature. (Inset) Averaged drop in
body temperature (maximal hypothermia)
measured 30 min after drug administration.
Means 6 SEM are shown. *Significantly dif-
ferent from wild-type (WT) mice, P , 0.05,
Student's t-test. Note that there is no signifi-
cant difference between genotypes in hypo-
thermic response to (1)-8-OHDPAT.
increased sensitivity to a spectrum of responses medi- muscarinic receptor number or responsiveness. There
were no differences in the number of oxotremorine bind-ated by muscarinic cholinergic receptors.
ing sites nor in the affinity of the receptor in wild-type
Muscarinic Agonist-Mediated Analgesia
in GRK5-KO Mice
Another well established manifestation of central mus-
carinic receptor stimulation is antinociception. Musca-
rinic agonists produce potent analgesia in tests as-
sessing central pain perception. To examine the effects
of GRK5 deletion on pain perception (Hartvig et al.,
1989), mice were challenged with oxotremorine and
tested in the hot-plate test (Konig et al., 1996; Gomeza
et al., 1999). Mice of either genotype, when injected with
vehicle, responded equally rapidly when placed on the
hot plate (Figure 5A). Oxotremorine-treated GRK5-KO
mice, however, responded to high temperature signifi-
cantly less well than did the wild-type control animals.
Moreover, these antinociceptive responses persisted
longer (Figure 5A) and were detected at a lower dose
of oxotremorine (Figure 5B) than in the wild-type mice.
Mice of different genotypes did not differ in their basal
response to the hot plate (wild type: 6.06 6 0.28 s;
GRK5-KO: 6.04 6 0.23 s).
To test whether the observed behavioral supersensi-
tivity of GRK5-KO mice is reflective of altered muscarinic
receptor signaling, and does not represent altered phar-
macokinetic or pharmacodynamic properties of oxo-
tremorine, we also treated mice with physostygmine,
which raises endogenous acetylcholine levels by inhib-
iting acetylcholinesterase (Galeotti et al., 1996). Physo-
stygmine (0.2 mg/kg, intraperitoneally [i.p.]) produced
significant analgesia in both GRK5-KO and wild-type
mice, but continued to invoke analgesia in GRK5-KO
mice even 90 min after injection, by which time the re-
sponsiveness of wild-type mice had returned to basal
levels (data not shown). These studies reveal that re-
gardless of the means of receptor stimulation, either Figure 3. Locomotor Response to Muscarinic and Dopaminergic
directly by exogenous agonist or indirectly by preventing Agonists in Mutant and Wild-Type Mice
degradation of endogeneous acetylcholine, the analge- (A) Effect of oxotremorine (0.05 mg/kg, i.p.) on horizontal activity.
(Inset) Overall decrease in activity (total horizontal activity countssic effects of muscarinic receptor stimulation in GRK5-
for 40 min in saline-treated wild-type mice: 3997 6 384, n 5 11; inKO mice are augmented and prolonged.
mutant mice: 4787 6 516, n 5 10) during 40 min after drug adminis-
tration. Means 6 SEM are shown. *Significantly different from wild-Impaired Muscarinic Receptor Desensitization
type mice, P , 0.05, Student's t-test.
in GRK5-KO Mice (B) Effect of apomorphine (3.0 mg/kg, subcutaneously) on vertical
The sensitivity of GRK5-KO mice to muscarinic agonists activity. Note that there is no significant difference between geno-
types in climbing response to apomorphine.suggests that there may be changes in either neuronal
Neuron
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Figure 5. Antinociceptive Effect of Oxotremorine in Hot Plate Test
in Mutant and Wild-Type Mice
(A) Time course of oxotremorine (0.05 mg/kg, i.p.) or saline (10 ml/
kg, i.p.) induced analgesia (% MPE 5 % Maximum Possible Effect).
To determine differences between mouse genotypes, a two-way
Figure 4. Tremor and Salivation in Mutant and Wild-Type Mice repeated analysis of variance was used and differences were identi-
(A) Tremor and (B) salivation following oxotremorine (0.2 mg/kg, fied using a two-tailed t-test contrast matrix. Significantly different
i.p.) in mutant and wild-type mice. Means 6 SEM are shown. To from wild-type mice, *P , 0.05.
determine differences between mouse genotypes, a two-way re- (B) Dose response of oxotremorine-induced analgesia 30 min after
peated measure analysis of variance was used and differences were drug administration. Each set of data was performed on independent
identified using a two-tailed t-test contrast matrix. *Significantly groups of 8±12 knockout and 11±15 wild-type animals. Means 6
different from wild-type mice, P , 0.05. SEM are shown. Significantly different from wild-type mice, *P ,
0.05, **P , 0.01; Student's t-test.
and GRK5-KO mouse brain regions (striatum, brainstem,
and hypothalamus) as determined by saturation binding
seen in striatum either by the same method or ex vivo,of [3H]oxotremorine (Table 1).
where the desensitization of muscarinic receptors wasPotential changes in receptor sensitivity were as-
induced in animals by systemic treatment with 0.5 mg/sessed indirectly by measuring receptor coupling to G
kg oxotremorine (i.p.) 30 min before sacrifice and prepa-proteins. In this approach, freshly dissociated brain
ration of striatum membranes (data not shown). By com-stem pieces were pre-exposed to millimolar concentra-
parison, isoproterenol-stimulated binding of [35S]GTPgStions of oxotremorine-M (a more stable analog of oxo-
through b-adrenergic receptors could be prevented bytremorine) (Birdsall et al., 1978) for 15 min to allow for
pretreatment with isoproterenol in brainstems from bothactivation and desensitization of muscarinic receptors
wild-type and GRK5-KO mice (data not shown).(Kunapuli et al., 1994; Bernard et al., 1998). After this
pre-exposure period, membranes were prepared and
Discussionassessed for [35S]GTPgS binding during a 5-min stimula-
tion in the presence of increasing concentrations of
Desensitization of GPCRs represents an important stepoxotremorine-M (Figure 6). Under these conditions, pre-
in agonist-dependent receptor regulation (Pitcher et al.,treatment with muscarinic agonist completely abolished
1998). Numerous in vitro studies have demonstrated theoxotremorine-stimulated binding of [35S]GTPgS to mem-
fundamental role of this process in cellular functions.branes prepared from wild-type animals, suggesting
However, few studies have been devoted to elucidationthat these receptors had been desensitized during pre-
of the function of these processes in vivo. The recenttreatment. However, oxotremorine pretreatment did not
availability of transgenic models, particularly the gener-reduce muscarinic receptor coupling to G proteins in
ation of knockout mice, has greatly facilitated evaluationbrain membranes from GRK5-KO mice, indicating that
of the physiological role of specific proteins at the levelwithout GRK5, these muscarinic receptors are appar-
ently resistant to desensitization. Similar results were of the whole organism. Genetic deletion of GRK5 has
Muscarinic Supersensitivity in GRK 5±Deficient Mice
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Table 1. Muscarinic Receptor Binding Sites in Brain Regions of Wild-Type (WT) and KO Mice
WT GRK5-KO
BMAX KD BMAX KD
Brain Region (fmol/mg) (nM) (fmol/mg) (nM)
Hypothalamus 101 6 15 6.5 6 2.7 117 6 11 8.3 6 2.0
Brainstem 101 6 20 5.2 6 0.9 94 6 11 5.4 6 0.8
Striatum 91 6 10 3.3 6 0.1 91 6 19 3.3 6 0.6
Binding was performed on membranes from different brain regions with increasing concentrations of 3H-oxotremorine-M (0±12 nM). Nonspecific
binding was determined with 10 mM unlabeled oxotremorine-M. Data are the mean 6 SEM of three experiments performed in duplicate.
been used here to gain insight into the functional role is unimportant in biological processes, but rather that
it plays little role in setting the basal tone of the signalingof this regulatory protein. This approach is particularly
pathway. In a transgenic animal that has lost a compo-valuable, since there are no useful pharmacological
nent that is involved in dampening a stimulatory signal,modulators of this protein known to date.
no effect may be seen until that signal is provided. UponFrom numerous in vitro studies, it is known that GRK5
challenge with the relevant agonist, the animal is nois involved in phosphorylation of several GPCRs, includ-
longer able to compensate to the same degree as hising subtypes of muscarinic receptors (Inglese et al.,
wild-type littermate. It is also possible that there may1993; Kunapuli et al., 1994; Premont et al., 1994; Menard
be functional substitutes for the missing GRK5 that allowet al., 1996; Tsuga et al., 1998). A loss of GRK5 would
the animal to maintain a normal phenotype. For example,be expected to result in decreased receptor phosphory-
other GRKs or downstream signaling elements such aslation, which appears to be critically important for recep-
protein kinase A may be involved in regulating the recep-tor desensitization following agonist stimulation (Pitcher
tors (Hausdorff et al., 1990). However, the apparent in-et al., 1998). However, previously it has not been deter-
ability of brain muscarinic receptors to desensitize inmined whether this will result in enhanced receptor re-
GRK5-KO animals argues that such compensation issponsiveness in vivo or which receptor populations are
minimal. Further, no obvious increases in the levels ofaffected. The present observations unequivocally dem-
other GRKs in the brain are apparent by Western blottingonstrate that not only are muscarinic receptors resistant
(data not shown).to desensitization in the GRK5-KO mouse, but they also
Behavioral analyses were performed after challengingappear to be supersensitive to muscarinic agonists.
animals with a number of agonists to seek out the spe-From initial characterization of the GRK5-KO mice, it
cific receptors affected by the loss of GRK5. Remark-became evident that under basal, unchallenged condi-
ably, we found no differences in cocaine-induced loco-tions, these mice demonstrate a very modest pheno-
motor responses and climbing responses following hightype, because only a slight decrease in body tempera-
doses of apomorphine, a direct D1/D2 dopamine recep-ture was found. This observation of a weak phenotype
tor agonist (Wilcox et al., 1980). Similarly, hypothermicshould not be interpreted to suggest that GRK5 function
responses to stimulation of serotonin 5-HT1A receptor
by 8-OH DPAT (Overstreet et al., 1998) did not differ
between the genotypes. These data suggest that the
relative responsiveness of dopamine receptors, affected
by cocaine and apomorphine, as well as the 5-HT1A
subtype of serotonin receptors, seems to be unchanged
by deletion of GRK5.
Nonetheless, the GRK5-KO mice were found to be
notably hypersensitive to behavioral effects of the non-
selective muscarinic agonist oxotremorine. The classi-
cal responses to muscarinic stimulation, such as hypo-
thermia, tremor, salivation, and locomotor suppression
(Lomax, 1970; Saligaut et al., 1985; Dilsaver and Alessi,
1988; Janowsky et al., 1994; Overstreet et al., 1998;
Gomeza et al., 1999) were enhanced and prolonged in
Figure 6. [35S]GTPgS Binding to Brainstem Membranes from Mutant mutant mice in comparison with littermate controls. Fur-
and Wild-Type Mice
ther, the antinociceptive effect of oxotremorine was also
Brainstem pieces were incubated at 378C, 15 min prior to membrane
significantly potentiated. The lack of selective agents topreparation in the presence or absence of 5 mM oxotremorine-M.
evaluate receptor subtype specificity precludes defini-[35S]GTPgS binding to membranes was determined after 5 min stimu-
tive clarification of the muscarinic receptor subtype in-lation with 0±200 nM oxotremorine-M. Total [35S]GTPgS binding is
portrayed after subtracting unstimulated [35S]GTPgS binding from volved. However, a recent report on M2 muscarinic re-
each point; data were analyzed by nonlinear regression using ceptor knockout mice strongly suggests that the vast
GraphPad Prism software. In the absence of agonist stimulation, majority of the behaviors evaluated here may be medi-
basal [35S]GTPgS binding: wild-type mice, 2748 6 143; GRK5-KO, ated by this receptor subtype (Gomeza et al., 1999).
2707 6 573 cpm. Oxotremorine pretreated wild-type brainstems
Therefore, behavioral supersensitivity to oxotremorinedid not converge to the nonlinear regression analysis, indicating
in GRK5-KO mice most likely reflects enhanced respon-that no oxotremorine-M concentration-dependent stimulation of
[35S]GTPgS binding occurs during the 5 min agonist treatment. siveness subsequent to impaired desensitization of M2
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muscarinic receptors. However, these data do not pre- the impairment of GRK-mediated desensitization may
contribute to the altered responsiveness of the recep-clude the possibility that other muscarinic receptors
tors involved in these conditions, such as dopamine andand/or other GPCRs could be affected in these mice.
opioid receptors.In addition, since M2 receptors are abundant in the car-
In summary, GRK5-KO mice demonstrate marked be-diovascular system, future studies in these animals
havioral supersensitivity to muscarinic agonist stimula-should be useful to evaluate the role of GRK5 in control-
tion. Importantly, the observed behavioral supersensi-ling cardiac responses.
tivity is correlated with an apparent lack of muscarinicSix GRKs have been identified to date, while more
receptor desensitization in functional biochemical assays.than 1500 GPCRs have already been cloned (Pitcher et
These data demonstrate, in an in vivo animal model,al., 1998). Thus, redundancy in the mechanisms of GPCR
that GRK5-mediated regulation of GPCR signaling isregulation, such as the involvement of one GRK in the
physiologically relevant and that muscarinic receptorsphosphorylation of multiple receptors, is to be expected.
are likely in vivo targets for this kinase.However, the large effect seen in muscarinic respon-
siveness in the GRK5-KO animals argues that remark-
Experimental Proceduresably distinct GPCR/GRK specificity does exist in vivo.
Establishing the portfolio of receptors regulated by
Targeted Deletion of the Mouse GRK5 Locus
each GRK in vivo is one of the attractive applications To create the Triple-Lox/GRK5 targeting vector, first a set of three
of GRK-KO animals. To date, it has been demonstrated Triple-Lox vectors was created as follows. The LoxL vector was
prepared from pBS II by creating a new multiple cloning site con-that supersensitivity to olfactory stimuli (Peppel et al.,
taining NotI and NheI sites, a loxP element, and HindIII and Sse8387I1997) and muscarinic cholinergic airway responsiveness
sites. The LoxC vector was created similarly with a new multiple(Walker et al., 1999) is present in GRK3-KO animals, that
cloning region containing NotI and Sse8387I sites, a loxP element,cardiac supersensitivity to b-adrenergic stimulation is SalI, HindIII, and MfeI sites, another loxP element, and AscI and
present in heterozygous GRK2-KO mice (Jaber et al., FseI sites. MC1-TK (thymidine kinase) (Mansour et al., 1988) and
1996; Rockman et al., 1998), and that supersensitivity PGK-NEO (neomycin resistance) (from pD383, kind gift of Rene Hen,
Columbia) cassettes were inserted irreversibly between these twoto light is present in GRK1-KO animals (Chen et al.,
loxP elements using the SalI, HindIII, and MfeI sites to create the1999). Other altered receptor responses are almost cer-
LoxC/TK-NEO vector. The LoxR vector was created similarly totain to be found in these various GRK-deficient animals.
contain a new multiple cloning site containing NotI, AscI, HindIII,
It is reasonable to postulate that apparent sensitiza- EcoRI, PmeI, MfeI, SalI, and FseI sites, and was further modified by
tion of a receptor response may reflect an actual loss of irreversible addition of the PGK-DT (diphtheria toxin) cassette (kind
gift of Akira Imamoto, University of Chicago) at the MfeI and SalIdesensitization of the receptor. A lack of oxotremorine-
sites to create the LoxR/DT vector.mediated desensitization in GRK5-KO mice was demon-
Phage l carrying fragments of the mouse GRK5 gene from thestrated biochemically in the [35S]GTPgS binding assay.
129/SVJ strain were obtained and sequenced as described (PremontIn wild-type animals, a 15 min pretreatment with a high et al., 1999). The 3-kb HindIII fragment containing exons 7 and 8
dose of oxotremorine desensitized the receptors, pre- (the gene fragment to be flanked by loxP sites, or floxed), and the
venting [35S]GTPgS binding in response to a second 5-kb NotI±XbaI fragment containing exons 5 and 6 (long recombina-
tion arm) were ligated into the HindIII and NotI±NheI sites of theaddition of oxotremorine. However, in GRK5-KO mouse
LoxL vector, respectively. The 1.5-kb HindIII±EcoRI gene fragmentbrain stem, oxotremorine pretreatment did not impede
from between exons 8 and 9 was ligated into those sites in theoxotremorine-stimulated [35S]GTPgS binding to mem-
LoxR/DT vector. The long recombination arm, loxP site, and gene
brane G proteins. This was true whether the receptor fragment to be floxed were excised from the LoxL vector with NotI
was exposed to oxotremorine in vivo or in vitro. These and Sse8387I and ligated into those sites of the LoxC/TK-NEO vec-
observations suggest that muscarinic receptors in GRK5- tor. The long recombination arm, floxed gene fragment, and floxed
TK-NEO marker cassette were excised from this vector with NotIKO mice are resistant to desensitization, which is most
and AscI and inserted into those sites in the LoxR/DT vector tolikely due to the loss of GRK5. It is important to note
create the final targeting construct (Figure 1A).that this altered desensitization was not accompanied
Growth and selection of targeted ES cells and creation of chimeric
by a measurable change in receptor number, as revealed mice was performed essentially as described (Hogan, 1994). The
by binding studies. Taken together with the behavioral targeting DNA was linearized by digestion with NotI and electropor-
data, this suggests that the apparent behavioral sensiti- ated into AK7 ES cells. Cells were selected for growth in media
containing 200 mg/ml G418, and surviving clones were tested forzation to muscarinic agonists may be due to apparent
proper integration by amplification of a DNA band from the PGKloss of receptor desensitization.
promoter of the NEO marker gene to a region near exon 9 adjacentOverstimulation of muscarinic receptors has been
to the targeting construct. The identity of positive clones was con-
implicated in the pathogenesis of several human con- firmed by Southern blotting of genomic DNA isolated from the cells
ditions, such as depression, stress responses, and and digested with SpeI, using a probe from adjacent to exon 9
(Figure 1A). A targeted cell clone with a normal karyotype was ex-multiple chemical sensitivities (Janowsky et al., 1994;
panded and 10 3 106 cells were transfected with 11.5 mg of pBS II-Overstreet et al., 1996; Markou et al., 1998; Sapolsky,
PGK-NLS/Cre recombinase DNA. The PGK-NLS/Cre plasmid con-1998). Moreover, rodent animal models of behavioral
tains the PGK promoter driving transcription of Cre recombinasemuscarinic supersensitivity have been developed for modified to contain a nuclear localization signal (from pNLS-Cre, a
these conditions (Orpen and Steiner, 1995; Overstreet kind gift of Samuel Aparicio, Cambridge, UK). Electroporated cells
et al., 1998). It would be of interest to use GRK5-KO were plated, and 2 days later split to varying densities, and then
selected for growth in the presence of 2 mM gangcyclovir. Survivingmice as test subjects to evaluate the role of GRK5-
clones were tested for deletion of the floxed TK-NEO marker cas-mediated receptor desensitization in these manifesta-
sette and the floxed GRK5 exon 7 and 8 fragment by amplificationtions. Behavioral sensitization has been suggested to
and by Southern blotting. A cell clone found to lack both floxed
be critically involved in drug dependence, tolerance, and cassettes was microinjected into day 3.5 C57BL/6J mouse blasto-
addiction (Nestler and Aghajanian, 1997). The present cysts, which were then injected into the uterus of a day 2.5 pseudo-
pregnant B6SJLF1/J mouse. Chimeric offspring were crossed withobservations raise the important question as to whether
Muscarinic Supersensitivity in GRK 5±Deficient Mice
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C57BL/6J mice to generate agouti pups that carried the deleted the same buffer and protein concentrations (50±100 mg/ tube) were
GRK5 gene. Heterozygote animals were interbred to obtain the wild- used. Saturation binding assays were performed as previously de-
type and homozygote GRK5-KO animals studied here. Genotyping scribed (Gillard et al., 1987) with increasing concentrations (0±12
was routinely performed on tail tip DNA using a PCR method utilizing nM) of [3H]oxotremorine-M (88.5 Ci/mmol, New England Nuclear,
three primers to simultaneously detect the wild-type and mutant Boston, MA). Nonspecific binding was determined in the presence
loci (Figure 1B). of 10 mM oxotremorine-M. Samples were incubated at 258C for 1
hr and then collected via a Brandel cell harvester onto GF/C filters
Western Blots (presoaked with 0.1% polyethylenimine). Filters were washed three
Mouse brain regions were dissected on ice, immediately frozen in times with ice-cold phosphate buffer (10 mM, pH 7.4). After drying,
liquid nitrogen, and stored for less than 1 week at 2808C. Crude radioactivity was counted in a liquid scintillation counter.
membranes were prepared from mouse brain regions by polytron
homogenization in sodium phosphate buffer (50 mM; pH 7.4) fol- [35S]GTPgS Binding to Brain Membranes
lowed by centrifugation at 20,000 3 g for 30 min. Aliquots (60 mg) Brain stems were divided bilaterally. Each half was subjected to a
of each sample were collected and centrifuged (5 min; 14,000 rpm, gentle manual dissociation of the tissue into pieces with a razor
Eppendorf 5414 centrifuge). Pellets were solubulized in lysing buffer blade. Tissue pieces were then incubated in the presence or ab-
(10 mM Tris [pH 7.4], 5 mM EDTA, protease inhibitor cocktail [Roche sence of 5 mM oxotremorine-M in 1 ml of assay buffer (50 mM Tris
Molecular Biochemicals, Indianapolis, IN], 1% Nonidet P-40 [Sigma, [pH 7.4], 100 mM NaCl, 10 mM MgCl2) per sample for 15 min at
St. Louis, MO]) and separated by 10% SDS-polyacrylamide gel elec- 378C. Samples were placed on ice and homogenized by polytron.
trophoresis. Proteins were transferred to Immobilon-P polyvinyli- Membrane preparation buffer (50 mM Tris [pH 7.4], 100 mM NaCl,
dene difluoride (PVDF) membranes (Millipore, Bedford, MA) and 1 mM EDTA, 5 mM MgCl2, 1 mM DTT) was added to each sample,
blotted with monoclonal anti-GRK5 (A16/17) [Oppermann et al., and crude membranes were prepared by centrifugation at 20,000 3
1996] followed by anti-mouse±horseradish peroxidase conjugated g for 20 min. Membranes were washed three times in the same
secondary antibody (Amersham, Piscataway, NJ). Bands were visu- buffer followed by centrifugation for 5 min at 20,000 3 g. Membranes
alized on autoradiographic film after enhanced chemilluminescent were finally resuspended in assay buffer containing 2 mM GDP, and
development (ECS, Amersham, Piscataway, NJ). protein concentrations were adjusted to provide 20 mg of protein
per assay tube. [35S]GTPgS binding was performed as described
Animal Treatment, Drugs, and Behavior previously (Lazareno, 1999). Increasing concentrations of oxo-
Littermate wild-type and GRK5-KO 3- to 4-month-old C57BL/63 tremorine-M were used in the presence of 100 pM [35S]GTPgS (1250
129SvJ mice were used in these experiments. Rectal body tempera- Ci/mmol, New England Nuclear) and 2 mM GDP. The reaction was
tures were determined using a digital thermometer (TH8, Physitemp, terminated after 5 min by rapid filtration over GF/C filters using
Clifton, NJ). The probe was inserted into the rectum and maintained a Brandel cell harvester (Brandel, Gaithersburg, MD). Filters were
until the temperature reading stabilized. washed three times with ice-cold 10 mM sodium phosphate buffer
Spontaneous open field locomotion and rearing behaviors of lit-
(pH 7.4) and then counted in a liquid scintillation counter.
termate wild-type and knockout mice of both genders were mea-
sured in an Omnitech digiscan activity monitor (42 cm2). Activity
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